本文選題：干擾素αb + 干擾素αb��； 參考：《中國藥房》2016年23期

【摘要】：目的:比較干擾素α1b與α2b治療慢性丙型肝炎的經(jīng)濟性。方法:采用回顧性研究方法,選擇114例接受干擾素治療的慢性丙型肝炎患者,將其中采用干擾素α1b治療的60例作為A組,采用干擾素α2b治療的54例作為B組,比較兩組患者的丙型肝炎病毒(HCV)-RNA轉陰率、丙氨酸轉氨酶(ALT)復常率和不良反應發(fā)生率,并進行藥物經(jīng)濟學分析。結果:A組患者治療4、12、24、36、48周時的HCV-RNA轉陰率分別為55.00%、71.67%、63.33%、61.67%、65.00%,B組患者在上述各時間的HCV-RNA轉陰率分別為64.81%、66.67%、62.96%、55.56%、61.11%,組間比較差異均無統(tǒng)計學意義(P0.05);治療結束時,A組患者的ALT復常率為95.23%,B組為96.10%,組間比較差異無統(tǒng)計學意義(P0.05);兩組患者各種不良反應發(fā)生率比較,差異均無統(tǒng)計學意義(P0.05),故采用最小成本法進行藥物經(jīng)濟學分析。A組的治療成本為13 216.56元,B組為7 929.60元,B組的成本明顯低于A組;敏感度分析得到同樣的結果。結論:干擾素α2b治療慢性丙型肝炎較干擾素α1b更為經(jīng)濟。
[Abstract]:Objective: to compare the economic efficiency of interferon 偽 1b and 偽 2b in the treatment of chronic hepatitis C.Methods: a retrospective study was carried out in 114 patients with chronic hepatitis C treated with interferon, 60 of whom were treated with interferon 偽 1b as group A and 54 as group B treated with interferon 偽 2b.The rates of HCV seroconversion, alanine aminotransferase (alt) reversion and adverse reactions were compared between the two groups, and the pharmacoeconomic analysis was carried out.Results at 48 weeks after treatment, the HCV-RNA negative conversion rate of group A was 55.00 and 71.67, respectively. The rate of ALT conversion in group B was 64.81and 64.81and 66.6762.9655.565.51, respectively. There was no significant difference between the two groups (P 0.05); at the end of the treatment, the ALT recovery rate of patients in group A was 95.2323.96.10, there was no significant difference between the two groups (P 0.05); the incidence of various adverse reactions in the two groups was higher than that in the control group.There was no significant difference between the two groups, so the cost of treatment in group A was 13 216.56 yuan and that in group B was 7 929.60 yuan, which was significantly lower than that in group A, and the sensitivity analysis showed the same result.Conclusion: interferon 偽 2b is more economical than interferon 偽 1b in the treatment of chronic hepatitis C.
【作者單位】： 成都市公共衛(wèi)生臨床醫(yī)療中心;
【基金】：國家科技重大專項課題(No.2012ZX10005004-003)
【分類號】：R512.63

【相似文獻】

相關期刊論文 前10條

1 高錦娟,紀莎;重組人干擾素α-2b致精神癥狀[J];藥物不良反應雜志;2003年05期

2 李堅;趙淑清;徐迎勝;;干擾素α-2b致急性炎癥性脫髓鞘性多發(fā)性神經(jīng)病[J];藥物不良反應雜志;2006年02期

3 國澤延;;干擾素α-1b重復治療慢性乙型病毒性肝炎26例療效觀察[J];當代醫(yī)學;2012年21期

4 陸堅,馬為民,王火生;干擾素抗體對干擾素α-1b療效影響的動態(tài)研究[J];臨床肝膽病雜志;2000年04期

5 王椿;干擾素在血液系統(tǒng)惡性腫瘤的治療價值[J];醫(yī)師進修雜志;2000年11期

6 王春生,吳晶;重組干擾素α-2a栓抗Ⅱ型單純皰疹病毒作用[J];中國醫(yī)院藥學雜志;2000年03期

7 賈青青,王曉玲;慢性乙型病毒性肝炎患者血清可溶性細胞間粘附分子-1水平與干擾素療效的關系[J];河北醫(yī)藥;2000年03期

8 周岳進;慢性乙型病毒性肝炎干擾素初治失敗后的治療[J];胃腸病學和肝病學雜志;2000年02期

9 毛長庚;干擾素引發(fā)全血象降低1例[J];中華肝臟病雜志;2001年06期

10 陳琦,石小巖;重組人干擾素α經(jīng)鼻腔給藥用于預防和治療上呼吸道病毒性感染的前景[J];中國醫(yī)院藥學雜志;2003年07期

相關會議論文 前10條

1 周岳進;;慢性乙型病毒性肝炎干擾素初治失敗后的治療[A];中國中西醫(yī)結合學會第十二次全國消化系統(tǒng)疾病學術研討會論文匯編[C];2000年

2 賈珍容;徐雪元;閔e，

本文編號：1766001